A Study to Evaluate the Quality of Life of Male and Female Adult Patients With Severe Refractory Atopic Dermatitis Treated With Dupilumab in Czech Republic

CompletedOBSERVATIONAL
Enrollment

146

Participants

Timeline

Start Date

December 30, 2022

Primary Completion Date

June 16, 2025

Study Completion Date

June 16, 2025

Conditions
Atopic Dermatitis
Trial Locations (1)

180 81

Investigational Site: Bulovka University Hospital, Prague

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT05527964 - A Study to Evaluate the Quality of Life of Male and Female Adult Patients With Severe Refractory Atopic Dermatitis Treated With Dupilumab in Czech Republic | Biotech Hunter | Biotech Hunter